Application of aescin and / or its salt compounds as adjuvant in vaccines
By combining saponin with antigen and equiping it in different vectors, the problem of limited types of adjuvants for existing vaccines and the inability of aluminum adjuvants to induce cellular immunity is solved, and comprehensive immune enhancement of antigens is achieved, which significantly improves humoral fluid and cells Immune response effect.
Patent Information
- Application Number
- CN202310047342.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-01-31
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-01-31
AI Technical Summary
There are limited types of vaccine adjuvants, especially aluminum adjuvants, which cannot induce cellular immune responses and have side effects, making it difficult to meet the needs of different diseases for immune response types.
Use saponin and/or its salt compounds as vaccine adjuvants to form immune complexes by binding to antigens and equipped with various carriers such as microemulsions, liposomes, aluminum salt nanoparticles, etc. to enhance body fluids and cells. Immune response.
Hornet saponin and/or its salt compounds can significantly increase the production of IgG1 and IgG2a antibodies, induce cytotoxic T cells, achieve comprehensive immune enhancement of antigens, solve the problems of lack of existing adjuvants and side effects, and have more extensive applications. potential.
Smart Images

Figure QLYQS_1 
Figure BDA0004056133440000021 
Figure HDA0004056133450000011
Abstract
Description
Technical Field
[0001] The present invention relates to an immune complex, which can obviously enhance the humoral immunity and cellular immune response of antigens when applied in a delivery system, can be used as a vaccine adjuvant and applied in vaccines, and belongs to the field of immunology. Background Art
[0002] Vaccination is one of the most remarkable health achievements in human history and one of the most cost-effective ways to prevent and control infectious diseases. Vaccines have eradicated smallpox, eliminated polio in most parts of the world, and reduced the mortality and incidence of many infectious diseases worldwide. Vaccines refer to immune preparations made from pathogenic microorganisms (such as bacteria, viruses, etc.) and their metabolites for the prevention of infectious diseases. Vaccines retain the characteristics of pathogenic microorganisms to stimulate the body's immune system, allowing the body's immune system to produce certain protective substances to prevent the harm of related pathogens. The immunogenicity of antigens alone is usually low, and after injection, they often cannot induce an effective immune response to fight the invasion of pathogens. Adjuvants are usually added to induce a protective immune response of sufficient strength. Therefore, the efficacy of vaccines depends not only on the antigen component, but also on the type of adjuvant that stimulates the immune system. Adjuvants refer to a class of substances that can increase the body's immune response to antigens or change the type of response after being injected before, mixed with, or simultaneously with antigens.
[0003] So far, the number of vaccine adjuvants approved for use in humans is very limited, a total of eight, including aluminum adjuvants, MF59, viral particles, AS04, AS03, AS01, CpG 1018 and Matrix-M. The types of immune responses induced by different adjuvants vary greatly. Different diseases also have very different requirements for immune response types. For example, common bacterial infectious diseases mostly require humoral immune responses to participate in the elimination of pathogens, while diseases such as intracellular bacteria, viruses and tumors require cellular immune responses to kill infected cells. Taking the most commonly used traditional aluminum adjuvant as an example, it can effectively stimulate the body to produce IgG1 antibodies and induce a strong humoral immune response. However, aluminum adjuvants cannot induce cellular immune responses, so the treatment effect on diseases such as intracellular bacteria, viruses and tumors that rely on cytotoxic T cell killing is very limited, and the human body may have adverse reactions such as fever and local redness and swelling after injection of aluminum adjuvants. In order to improve the effectiveness of vaccines and broaden the scope of application of adjuvants, the development of new, safe and effective vaccine adjuvants has become an important strategic goal of the country.
[0004] Therefore, the development of novel vaccine adjuvants that can induce both humoral and cellular immune responses is very important for human health. Summary of the invention
[0005] In order to solve the problems that there are few types of existing vaccine adjuvants and aluminum adjuvants cannot induce cellular immune responses, the inventors found that aescin and / or its salt compounds can significantly improve humoral immunity and cellular immune responses, have obvious immunoenhancing effects, and have vaccine adjuvant effects.
[0006] One of the purposes of the present invention is to provide the use of aescin as an adjuvant and the use of aescin as an adjuvant in vaccines, wherein the aescin is aescin or aescin salt compound. Aescin is a seed extract of the Aesculus plant Castanea japonica, which has pharmacological effects such as increasing venous tension, improving blood circulation and correcting brain dysfunction. At present, it is mainly used in the clinical treatment of brain diseases such as cerebral edema in the form of tablets and injections.
[0007] The inventors of the present invention have found that aescin and / or its salt compounds can enhance humoral and cellular immune responses and can be used as vaccine adjuvants.
[0008] One of the objects of the present invention is to provide an immune complex, which comprises an antigen and aescin and / or aescin salt compound.
[0009] The antigens described in the present invention include one or more of proteins, polypeptides, nucleic acids, tumor cell lysates, virus or bacterial lysates, bacterial cell membranes, mycoplasma cell membranes, viral envelopes, exosomes, bacterial antigens, tumor cell lysate antigens, tumor cell membrane vesicle antigens, tumor cell exosome antigens, model antigens such as chicken ovalbumin OVA, and the like.
[0010] The aescin salt compound is characterized by being a compound represented by the following structural formula (I), wherein R in the structural formula is one or more of glycine, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine and histidine, and various metal salts, including one of sodium, potassium, zinc, aluminum, iron, zirconium, calcium, manganese and magnesium.
[0011]
[0012] The immune complex of the present invention is characterized in that the weight ratio between the antigen and aescin is 1:0.1-100, preferably, the weight ratio is 1:1-50, and further preferably, the mass ratio is 1:2-10.
[0013] One of the purposes of the present invention is to protect immune complexes based on aescin and / or its salt compounds, characterized in that antigens, aescin and / or aescin salt compounds can be co-loaded in a carrier, and the carrier includes but is not limited to organic particles, such as microspheres and microcapsules, emulsions, liposomes, metal-organic skeleton compounds, gels, polystyrene particles, dendritic molecular compounds, polymer particles, etc.; inorganic particles: gold nanoparticles, iron oxide particles, mesoporous silica particles, aluminum salt particles, calcium phosphate particles, calcium carbonate particles, etc.; bionic particles, such as one or more of cell carriers, bacterial carriers, exosomes, virus particles, virus-like particles, etc., to enhance the immune response.
[0014] One of the purposes of the present invention is to protect immune complexes based on aescin and / or its salt compounds, characterized in that antigens, aescin and / or aescin salt compounds can be encapsulated in different carriers and then mixed for administration, wherein the carriers include but are not limited to organic microparticles, such as microspheres and microcapsules, emulsions, liposomes, metal-organic skeleton compounds, gels, polystyrene microparticles, dendritic molecular compounds, polymer microparticles, etc.; inorganic microparticles: gold nanoparticles, iron oxide microparticles, mesoporous silica microparticles, aluminum salt microparticles, calcium phosphate microparticles, calcium carbonate microparticles, etc.; bionic microparticles, such as one or more of cell carriers, bacterial carriers, exosome virus particles, virus-like particles, etc., to enhance immune response.
[0015] Preferably, the carrier is one or more of microemulsion, aluminum salt microparticles, and liposomes. Further preferably, the microemulsion contains squalene, Tween 80, and egg yolk lecithin; the aluminum salt microparticles contain chondroitin sulfate, aluminum sulfate and / or aluminum hydroxide; and the liposomes contain DOPC, cholesterol, and DSPE-PEG.
[0016] One of the purposes of the present invention is to protect immune complexes based on aescin and its salt compounds, characterized in that other adjuvants can be added to the complexes for combined use to further enhance the immune response, and the additional adjuvants include but are not limited to: aluminum adjuvants; antigen-associated molecular pattern adjuvants: Toll-like receptor agonists: peptidoglycan, lipoteichoic acid, MPLA, imiquimod, resiquimod, CpG-ODN, bacterial flagellin, Poly I:C; RIG-I-like receptor agonists: 3pRNA, short double-stranded RNA; NOD-like receptor agonists: muramyl dipeptide (MDP), N-acetylglucosamine; C-type lectin receptor: β-glucan, trehalose diborate; STING agonists; bacterial toxins and their derivatives: cholera toxin (CT), Escherichia coli heat-labile enterotoxin (LT), cholera toxin B subunit; saponins: QS21, tomatidine, Quil-A; cytokines: GM-CSF, IL-2, IL-12, IL-6, IFN-γ, lymphocyte chemotactic factor; other adjuvants: one or more complexes of heat shock protein, A151, GTP-GDP, and dimethyldioctadecyl quaternary ammonium bromide (DDA).
[0017] Preferably, the additional adjuvant is one or more of aluminum adjuvant, CpG-ODN, and MPLA.
[0018] The present invention has found for the first time that aescin and / or its salt compound has an immune adjuvant effect, and studies its application as a vaccine adjuvant. In addition, the types of adjuvants in this area are very limited, and the most commonly used aluminum adjuvant can only induce humoral immunity, and CpG-ODN has more advantages in inducing cellular immunity, but there is still a lack of adjuvants that can simultaneously improve humoral immunity and cellular immune response. The present invention finds that aescin and / or its salt compound can effectively induce IgG1 and IgG2a antibody production, play an adjuvant role, and simultaneously induce humoral immunity and cellular immune response, which is more comprehensive than the adjuvant effect of conventional aluminum adjuvants and CpG-ODN. At the same time, the present invention also finds that aescin and / or its salt compound can be applied to a variety of carriers, and can synergistically play an adjuvant role in a variety of vaccine carriers of different properties such as microemulsions, aluminum salt nanoparticles and liposomes, enhance its adjuvant function, and simultaneously improve humoral immunity and cellular immune response. Further, the present invention also found that after aescin and / or its salt compound is used in combination with adjuvants such as CpG-ODN and MPLA, the ability of aescin to induce cellular immune response can be further improved, and the production of cytotoxic T cells can be effectively induced. It can be seen that aescin and / or its salt compound has a synergistic effect with conventional immune adjuvants. Currently, the only reported saponin adjuvant is QS-21, which is mainly used as one of the components of AS01 adjuvant and is used in combination with MPLA to make liposome adjuvants. It is currently mainly used in herpes zoster and malaria vaccines, and has a narrow range of applications. Although QS-21 can induce humoral and cellular immune responses, QS-21 can only be extracted from the bark of the soap bark tree in South America, and there are problems such as low purity, low yield and poor stability, which greatly limits the use of adjuvants in my country's vaccines. Secondly, there are many types of saponins, but we only found that aescin and / or its salt compound can enhance the body's humoral and cellular immune responses and can be used as a vaccine adjuvant. At the same time, compared with QS-21, aescin and / or its salt compounds are easy to obtain in my country, and the purity and yield are well guaranteed. At the same time, in terms of effect, aescin and / or its salt compounds can also improve humoral immunity and cellular immune response at the same time, and can be used in combination with a variety of adjuvants including MPLA to play a synergistic effect, and can be used as a better saponin adjuvant than QS-21. The research results of the present invention provide a new adjuvant that can induce humoral immunity and cellular immunity at the same time in the vaccine field, solving the problems of the existing adjuvant types, difficulty in obtaining, and large side effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 These are the results of specific antibodies IgG / IgG1 / IgG2a in the serum of mice immunized with a mixture of five saponins and OVA by subcutaneous injection at the base of the tail.
[0020] Figure 2This is the result of specific antibody IgG / IgG1 / IgG2a in the serum of mice immunized with aescin and OVA loaded into microemulsion and injected subcutaneously at the base of the tail.
[0021] Figure 3 This is the result of loading aescin into liposomes and mixing it with OVA, then injecting it subcutaneously at the base of the tail to immunize mice with specific antibodies IgG / IgG1 / IgG2a in the serum.
[0022] Figure 4 This is the result of specific antibody IgG / IgG1 / IgG2a in the serum of mice immunized with aluminum salt nanoparticles loaded with aescin and OVA and injected subcutaneously at the base of the tail.
[0023] Figure 5 This is the result of specific antibody IgG / IgG1 / IgG2a in the serum of mice immunized with a mixture of aescin and OVA and aluminum gel after subcutaneous injection at the base of the tail.
[0024] Figure 6 This is the result of specific antibody IgG / IgG1 / IgG2a in the serum of mice immunized by subcutaneous injection at the base of the tail after loading aescin and OVA into microemulsion and adding adjuvant MPLA.
[0025] Figure 7 This is the result of loading sodium aescinate into liposomes, mixing with OVA solution and adding adjuvant MPLA, and then subcutaneously injecting into the base of the tail to immunize mice with specific antibodies IgG / IgG1 / IgG2a in the serum.
[0026] Figure 8 This is the result of specific antibody IgG / IgG1 / IgG2a in the serum of mice immunized with aescin and OVA loaded into microemulsion and added with adjuvant CpG, followed by subcutaneous injection at the base of the tail.
[0027] Fig. 9 The results of in vivo CTL detection in mice after subcutaneous injection at the base of the tail after loading aescin and OVA into microemulsion and adding adjuvant MPLA.
[0028] Fig.10 The results of in vivo CTL detection after mice were immunized by subcutaneous injection at the base of the tail after loading aescin and OVA into microemulsion and adding adjuvant CpG. DETAILED DESCRIPTION
[0029] The following examples are further explanations of the present invention, but are by no means limitations of the scope of the present invention. The present invention will be further described in detail below with reference to the examples, but it should be understood by those skilled in the art that the present invention is not limited to these examples and the preparation methods used. Moreover, those skilled in the art may carry out equivalent substitutions, combinations, improvements or modifications to the present invention based on the description of the present invention, but these will all be included within the scope of the present invention.
[0030] Example 1
[0031] First, using ovalbumin (OVA) as an antigen, the immunostimulatory effects of five saponins (ginsenoside, saikosaponin, notoginsenoside, soybean saponin, and aescin) were systematically evaluated after subcutaneous injection at the base of the tail. Aescin (Esc), ginsenoside (Gin), saikosaponin (Sai), and notoginsenoside (Not) were dissolved in DMSO to prepare a 2 mg / ml stock solution, and soybean saponin (Soy) and ovalbumin (OVA) were dissolved in water for injection to prepare a 2 mg / ml stock solution. 10 μl of the saponin solution and 5 μl of the OVA solution were mixed, and 85 μl of water for injection were added. C57BL / 6 mice were subcutaneously injected with 100 μl of the mixed solution containing 20 μg of saponin and 10 μg of OVA at the base of the tail on days 0, 14, and 21, respectively. On the 27th day, blood was collected from the eye sockets and centrifuged at 8000 rpm for 10 min before the supernatant was collected. OVA-specific antibodies IgG / IgG1 / IgG2a were determined by ELISA. The results are shown in Figure 1 . Figure 1 The results showed that the immunogenicity of free OVA was low, and the IgG / IgG1 in the serum of mice after immunization was only slightly increased, but there was no significant difference with the PBS group. In the mixed solution of five saponins and OVA, the antibody levels of ginsenoside, bupleurum saponin, notoginseng saponin and soybean saponin groups were consistent with free OVA, which showed that none of the above saponins could induce immune response and had no immune adjuvant effect. Only aescin could significantly increase the IgG / IgG1 / IgG2a antibody level (****, p<0.0001). The results showed that only aescin had a significant immune enhancement effect and could enhance both humoral and cellular immune responses. Figure 1 In the experiment, PBS was used as the blank group, OVA was used as the free OVA group, OVA+Gin represented the mixed solution group of OVA and ginsenoside, OVA+Sai represented the mixed solution group of OVA and saikosaponin, OVA+Not represented the mixed solution group of OVA and notoginseng saponin, OVA+Soy represented the mixed solution group of OVA and soybean saponin, and OVA+Esc represented the mixed solution group of OVA and aescin.
[0032] Example 2
[0033] The preparation method of microemulsion (NE) is as follows: 0.2g of egg yolk lecithin is dissolved in 0.5g of squalene, 0.2g of Tween 80 is dissolved in water for injection, and the mixture is mixed to form colostrum. The colostrum is homogenized by high pressure to form 40ml of microemulsion (NE), 312.5μl of 37.5mM aluminum sulfate aqueous solution is added, and the mixture is vortexed to obtain the microemulsion.
[0034] The preparation method of microemulsion (NE-Esc) loaded with OVA and aescin is as follows: dissolve aescin in methanol to prepare a stock solution of a certain concentration, take an appropriate amount of the methanol solution of aescin and remove the methanol by rotary evaporation, add the above-prepared 400μl NE and 210μl Hepes buffer (100mM, pH 8.0), vortex and water bath sonicate for 3min, then add the prescribed amount of OVA solution, vortex mix, and add 40μl Al2(SO4)3 solution (0.075mol / L) dropwise to obtain the product.
[0035] C57BL / 6 mice were subcutaneously injected with 100 μl of a mixture containing 20 μg saponin and 10 μg OVA at the base of the tail on days 0, 14, and 21. Blood was collected from the eye sockets on day 27, and the supernatant was collected after centrifugation at 8000 rpm for 10 min. OVA-specific antibodies IgG / IgG1 / IgG2a were measured by ELISA. The results are shown in Figure 2 . Figure 2 The results showed that the IgG and IgG1 antibodies of the microemulsion loaded with OVA were significantly increased compared with the PBS group (**, p<0.01), while there was no significant difference in IgG2a, indicating that it mainly induced humoral immunity and had poor effects on cellular immunity. After aescin and OVA were co-loaded in the emulsion, IgG and IgG1 antibodies were significantly increased compared with free OVA (****, p<0.0001), and also significantly increased compared with the microemulsion loaded with OVA (**, p<0.01), indicating that aescin has the effect of inducing humoral immune response. From the results of IgG2a antibodies, OVA had no significant effect on IgG2a antibodies after being loaded into the microemulsion, while the microemulsion co-loaded with OVA and aescin had a significant increase compared with OVA and the microemulsion loaded with OVA (****, p<0.0001), indicating that aescin effectively improved the ability of microemulsion to induce cellular immune response. The above results show that aescin can not only synergistically improve the adjuvant efficacy of microemulsion, but also effectively promote humoral immunity and cellular immune response at the same time, especially significantly improving the immune adjuvant effect of microemulsion in cellular immunity. In the figure, PBS is the blank group, OVA is the free OVA group, NE represents the microemulsion group loaded with OVA, and NE-Esc represents the microemulsion group loaded with OVA and aescin.
[0036] Example 3
[0037] The liposome (Lip) preparation method is as follows: 6 mg DOPC, 2 mg cholesterol and 1.5 mg DSPE-PEG were weighed and dissolved in chloroform, the organic solvent was removed by rotary evaporation, 2 ml of aqueous solution containing 200 μg OVA was added to hydrate the film, and the probe was sonicated at 150w for 5 min under ice bath conditions.
[0038] The preparation method of liposomes loaded with aescin (Lip-Esc) is as follows: 6 mg DOPC, 2 mg cholesterol and 1.5 mg DSPE-PEG are weighed and dissolved in chloroform, a methanol solution containing 400 μg aescin is added, the organic solvent is removed by rotary evaporation, an appropriate amount of water for injection is added to hydrate the film, the probe is ultrasonicated at 150w for 5min under ice bath conditions, and an OVA aqueous solution is added to make its final concentration 0.1 mg / ml.
[0039] C57BL / 6 mice were injected subcutaneously at the base of the tail with 100 μl of Lip and Lip-Esc, which contained 20 μg of saponin and 10 μg of OVA, on days 0, 14, and 21, respectively. Blood was collected from the eye sockets on day 27, and the supernatant was collected after centrifugation at 8000 rpm for 10 min. The OVA-specific antibody IgG / IgG1 / IgG2a was determined by ELISA. The results are shown in Figure 3 . Figure 3 The results showed that compared with free OVA, the Lip group and OVA only had a certain improvement in IgG (*, p<0.05), but did not increase IgG1 and IgG2a antibodies, indicating that liposome-encapsulated OVA only has a weak immunostimulatory effect and can only induce a weak humoral immune response. Compared with OVA and Lip, Lip-Esc had a significant increase in IgG / IgG1 / IgG2a. (****, p<0.0001). The above results show that loading aescin into liposomes can not only synergistically improve the level of humoral immune response, but also induce cellular immunity. The adjuvant effect is further enhanced and is reflected in both humoral and cellular immune responses. It can be seen that aescin can effectively promote humoral immunity and cellular immunity at the same time. Figure 3 In the experiment, PBS was used as the blank group, OVA was used as the free OVA group, Lip represented the liposome group with added OVA, and Lip-Esc represented the liposome group with added OVA and aescin.
[0040] Example 4
[0041] The preparation method of OVA-loaded aluminum salt nanoparticles (ACN) is as follows: 80 μl of Hepes solution (10 mM, pH 6.8), 75 μl of chondroitin sulfate solution (10 mg / ml), and 10 μl of OVA (10 mg / ml) are mixed, and 110 μl of Al2(SO4)3 solution is added dropwise while vortexing.
[0042] The preparation method of aluminum salt nanoparticles (ACN-Esc) loaded with sodium aescinate and OVA is as follows: take 80μl Hepes solution (10mM, pH 6.8), 75μl chondroitin sulfate solution (10mg / ml), 10μl OVA (10mg / ml) and 20μl sodium aescinate (10mg / ml), mix them, and add 110μl Al2(SO4)3 solution while vortexing.
[0043] C57BL / 6 mice were injected subcutaneously at the base of the tail with 100 μl of ACN and ACN-Esc, which contained 20 μg of saponin and 10 μg of OVA, on days 0, 14, and 21, respectively. Blood was collected from the eye sockets on day 27, and the supernatant was collected after centrifugation at 8000 rpm for 10 min. The OVA-specific antibody IgG / IgG1 / IgG2a was determined by ELISA. The results are shown in Figure 4 . Figure 4 The results showed that the IgG and IgG1 antibodies of the aluminum salt nanoparticles loaded with OVA were significantly increased compared with the OVA group (**, p<0.01), while there was no significant difference in IgG2a. After sodium aescinate and OVA were co-loaded in aluminum salt nanoparticles, IgG and IgG1 antibodies were significantly increased compared with free OVA (****, p<0.0001), and were also significantly increased compared with aluminum salt nanoparticles loaded with OVA (**, p<0.01). Its IgG2a antibody was also significantly increased compared with free OVA and aluminum salt nanoparticles (**, p<0.01). The above results show that after sodium aescinate is loaded into aluminum salt nanoparticles, its adjuvant effect will be further enhanced, which can be manifested in both humoral and cellular immunity. It can be seen that aescinate can effectively promote humoral immunity and cellular immunity at the same time, especially in humoral immunity, which significantly improves the immune adjuvant effect of aluminum salt nanoparticles. Figure 4 In the experiment, PBS was used as the blank group, OVA was used as the free OVA group, ACN represented the aluminum salt nanoparticle group with added OVA, and ACN-Esc represented the aluminum salt nanoparticle group with added OVA and aescin.
[0044] Example 5
[0045] The preparation method of aluminum gel (Algel) for adsorbing OVA is as follows: 20 μl of aluminum gel is mixed with an appropriate amount of OVA solution to prepare a solution with a final concentration of 0.05 mg / ml OVA.
[0046] The preparation method of aluminum gel (Algel) for adsorbing OVA and sodium aescinate is as follows: 20 μl of aluminum gel is mixed with appropriate amounts of OVA and sodium aescinate solution to prepare a solution with a final concentration of 0.05 mg / ml OVA and 0.5 mg / ml sodium aescinate.
[0047] C57BL / 6 mice were subcutaneously injected with 100 μl of Algel and Algel-Esc containing 50 μg of saponin and 5 μg of OVA at the base of the tail on days 0, 14, and 21, respectively. Blood was collected from the eye sockets on day 27, and the supernatant was collected after centrifugation at 8000 rpm for 10 min. OVA-specific antibodies IgG / IgG1 / IgG2a were measured by ELISA. The results are shown in Figure 5 . The results showed that after OVA was mixed with aluminum gel, IgG and IgG1 antibodies were significantly increased (**, p<0.01), while IgG2a had no significant difference, indicating that aluminum gel can only produce humoral immune response, but lacks cellular immune response. After sodium aescinate and OVA were co-adsorbed on aluminum gel, IgG and IgG1 antibodies were significantly increased compared with free OVA (****, p<0.0001), and also significantly increased compared with aluminum gel adsorbed with OVA (**, p<0.01). Its IgG2a antibody was also significantly increased compared with free OVA and aluminum gel adsorbed with OVA (*, p<0.05). The above results show that after sodium aescinate is loaded into aluminum gel, its adjuvant effect will be further enhanced, which can be manifested in both humoral and cellular immunity. It can be seen that aescinate can effectively promote humoral immunity and cellular immunity at the same time, especially in humoral immunity, which significantly improves the immune adjuvant effect of aluminum gel. Figure 5 In the experiment, PBS was used as the blank group, OVA was used as the free OVA group, Algel represented the aluminum gel group adsorbing OVA, and Algel-Esc represented the aluminum gel group adsorbing both OVA and aescin.
[0048] Example 6
[0049] The preparation method of NE-Esc is as described in Example 2
[0050] The preparation method of NE-MEsc is as follows: dissolve aescin and MPLA in methanol and ethanol respectively to prepare a certain concentration of stock solution, take an appropriate amount of aescin methanol solution and MPLA ethanol solution and remove the organic solvent by rotary evaporation, add 400μl NE and 210μl Hepes buffer (100mM, pH 8.0), vortex and water bath ultrasonic for 3min, then add the prescribed amount of OVA solution, vortex to mix, and add 40μl Al2(SO4)3 solution (0.075mol / L) dropwise to obtain.
[0051] C57BL / 6 mice were subcutaneously injected with 100 μl of the above preparation containing 20 μg saponin, 10 μg OVA and 5 μg MPLA at the base of the tail on days 0, 14 and 21. Blood was collected from the eye sockets on day 27, and the supernatant was collected after centrifugation at 8000 rpm for 10 min. OVA-specific antibody IgG / IgG1 / IgG2a was measured by ELISA. The results are shown in Figure 6The results showed that the IgG / IgG1 / IgG2a antibodies of NE-MEsc were significantly higher than those of PBS group. At the same time, after adding MPLA adjuvant, the IgG / IgG1 / IgG2a antibodies of NE-MEsc were significantly higher than those of NE-Esc (****, p<0.0001). The above results show that the combined use of aescin and MPLA can further enhance the immune enhancement effect. It can be seen that aescin and MPLA have a synergistic effect, which can greatly improve the immune effect of the immune complex. Figure 6 In the figure, PBS was used as the blank group, NE-Esc represented the microemulsion loaded with OVA and aescin, and NE-MEsc represented the microemulsion co-loaded with OVA, aescin and MPLA.
[0052] Example 7
[0053] The preparation method of EsM, i.e., a mixed solution of sodium aescinate, MPLA and OVA, is as follows: prepare 1 mg / ml sodium aescinate aqueous solution, 1 mg / ml MPLA ethanol solution and 1 mg / ml OVA aqueous solution, mix to obtain a mixed solution, and add water for injection to 1 ml.
[0054] The preparation method of Lip-M, i.e., the MPLA-loaded liposome and OVA mixed group, is as follows: 6 mg DOPC, 2 mg cholesterol and 1.5 mg DSPE-PEG are weighed and dissolved in chloroform, an appropriate amount of ethanol solution containing MPLA is added, the organic solvent is removed by rotary evaporation, an appropriate amount of water for injection is added to hydrate the film, the probe is ultrasonicated at 150w for 5min under ice bath conditions, and OVA aqueous solution is added to make its final concentration 0.1 mg / ml.
[0055] The preparation method of Lip-MEs, i.e., liposomes co-loaded with sodium aescinate and MPLA and a mixed group with OVA, is as follows: 6 mg DOPC, 2 mg cholesterol and 1.5 mg DSPE-PEG are weighed and dissolved in chloroform, an appropriate amount of ethanol solution containing MPLA is added, the organic solvent is removed by rotary evaporation, an appropriate amount of aqueous solution containing sodium aescinate is added to hydrate the film, the probe is ultrasonicated at 150w for 5min under ice bath conditions, and an OVA aqueous solution is added to make its final concentration 0.1 mg / ml.
[0056] C57BL / 6 mice were subcutaneously injected with 100 μl of aspirin 20 μg, OVA 10 μg, and MPLA 5 μg at the base of the tail on days 0, 14, and 21. Blood was collected from the eye sockets on day 27, and the supernatant was collected after centrifugation at 8000 rpm for 10 min. OVA-specific antibodies IgG / IgG1 / IgG2a were measured by ELISA. The results are shown in Figure 7. The results showed that the IgG / IgG1 / IgG2a antibody levels of Lip-MEs were significantly higher than those of the mixed solution of free OVA, MPLA and sodium aescinate (****, p<0.0001). At the same time, after adding MPLA adjuvant, Lip-MEs significantly increased the IgG / IgG1 / IgG2a antibody levels compared with the Lip-M group loaded with MPLA alone (*, p<0.05). The above results indicate that sodium aescinate can significantly enhance cellular and humoral immune responses, and its immune enhancement effect is further enhanced when used in combination with MPLA. It can be seen that aescinate and MPLA have a synergistic effect, which can greatly enhance the immune effect of the immune complex. Figure 7 In the figure, EsM represents a mixed solution of sodium aescinate, MPLA and OVA, Lip-M represents a mixture of MPLA-loaded liposomes and OVA, and Lip-MEs represents a mixture of MPLA-loaded liposomes with sodium aescinate and OVA.
[0057] Example 8
[0058] The preparation method of NE-Esc is as described in Example 2
[0059] The preparation method of NE-CEsc is as follows: dissolve aescin in methanol to prepare a stock solution of a certain concentration, take an appropriate amount of aescin methanol solution and remove the organic solvent by rotary evaporation, add 400μl NE and 210μl Hepes buffer (100mM, pH 8.0), vortex and ultrasonicate in a water bath for 3min, then add the prescribed amount of OVA solution, vortex to mix, add 40μl Al2(SO4)3 solution (0.075mol / L) dropwise, and then add CpG solution dropwise while vortexing to obtain the product.
[0060] C57BL / 6 mice were subcutaneously injected with 100 μl of the above preparation containing 20 μg saponin, 10 μg OVA and 1 μg CpG at the base of the tail on days 0, 14 and 21. Blood was collected from the eye sockets on day 27, and the supernatant was collected after centrifugation at 8000 rpm for 10 min. OVA-specific antibodies IgG / IgG1 / IgG2a were measured by ELISA. The results are shown in Figure 8 . The results showed that the IgG / IgG1 / IgG2a antibody levels of NE-CEsc were significantly higher than those of PBS group. At the same time, after adding CpG adjuvant, the IgG / IgG1 / IgG2a antibodies of NE-CEsc were significantly higher than those of NE-Esc (****, p<0.0001). The above results indicate that the combined use of aescin and CpG can further enhance the immune enhancement effect. It can be seen that aescin and CpG have a synergistic effect, which can greatly improve the immune effect of the immune complex. Figure 8In the figure, PBS was used as the blank group, NE-Esc represented the microemulsion loaded with OVA and aescin, and NE-CEsc represented the microemulsion co-loaded with OVA, aescin and CpG.
[0061] Example 9
[0062] NE and NE-MEsc were prepared as described in Example 6, and NE-Esc was prepared as described in Example 2. C57BL / 6 mice were subcutaneously injected with 100 μl of the above preparation containing 20 μg saponin, 10 μg OVA and 5 μg MPLA at the base of the tail on days 0, 14 and 21, respectively. The spleen cells of blank C57BL / 6 mice were obtained after lysing red blood cells on day 27, and were divided into two and incubated with PBS and SIINFEKL respectively, and then the cells were treated with low and high concentrations of CFSE respectively. Finally, the two cells were evenly mixed and injected into the test mice by tail vein injection. The injection volume for each mouse was 200 μl, containing 1×10 7 16-24 hours later, mice were killed by cervical dislocation, and spleen cells were obtained by grinding and lysing red blood cells. The killing rate was detected by flow cytometry and calculated. CTL results can be found in Fig. 9 The results showed that NE had almost no killing effect on target cells, NE-Esc could improve the killing efficiency of CTL (*, p<0.05), and NE-MEsc could greatly improve the killing efficiency, which was 5.2 times and 4.3 times of NE and NE-Esc groups respectively (****, p<0.0001). The above results show that aescin can significantly induce the production of cytotoxic T cells and significantly improve the cellular immune response. When used in combination with MPLA, its immune enhancement effect is further enhanced. It can be seen that aescin and MPLA have a synergistic effect, which can greatly improve the immune effect of the immune complex. Fig. 9 In the figure, NE represents microemulsion loaded with OVA, NE-Esc represents microemulsion co-loaded with OVA and aescin, and NE-MEsc represents microemulsion co-loaded with OVA, aescin and MPLA.
[0063] Example 10
[0064] NE and NE-CEsc were prepared as described in Example 8, and NE-Esc were prepared as described in Example 2. C57BL / 6 mice were subcutaneously injected with 100 μl of saponin 20 μg, OVA 10 μg and CpG 1 μg at the base of the tail on days 0, 14 and 21, respectively. Target cells were prepared as described in Example 8 and infused back into the mice to be tested for flow cytometry detection. CTL results are shown in Fig.10. The results showed that NE had almost no killing effect on target cells, NE-Esc could improve the killing efficiency of CTL (*, p<0.05), and the killing efficiency of NE-CEsc was the highest, which was significantly different from the other groups (****, p<0.0001), which was 5.4 times and 4.6 times that of NE and NE-Esc groups, respectively. The above results show that aescin can significantly induce the production of cytotoxic T cells and significantly improve cellular immune response, and its immune enhancement effect is further enhanced when combined with CpG. It can be seen that aescin and CpG have a synergistic effect, which can greatly improve the immune effect of the immune complex. Fig.10 In the figure, NE represents microemulsion loaded with OVA, NE-Esc represents microemulsion co-loaded with OVA and aescin, and NE-CEsc represents microemulsion co-loaded with OVA, aescin and CpG.
[0065] In summary, aescin and / or its salt compound has an immune adjuvant effect, while other saponins do not have an immune adjuvant effect. Meanwhile, aescin and / or its salt compound, relative to conventional aluminum adjuvant, can not only induce the body to produce humoral immunity, but also produce cellular immunity, and the immune adjuvant effect is more comprehensive. Secondly, aescin and / or its salt compound can not only be used alone to exert the immune adjuvant effect, but also can be used in conjunction with other adjuvants (such as MPLA, CpG), further enhance the immune effect of other adjuvants, i.e., produce synergy with other adjuvants. In addition, aescin and / or its salt compound is convenient to use, not only can be used as a preparation, but also can be contained in a carrier of different properties and functions, and a synergistic effect is exerted with a variety of carriers, further improving the immune adjuvant effect. It can be seen that the present invention has found that aescin and / or its salt compound can be used as an immune adjuvant, and aescin and / or its salt compound is used as an immunopotentiator, which can significantly enhance the immunogenicity of the antigen, and can be used as a vaccine adjuvant. The results of animal experiments show that the combination of aescin and antigen can significantly increase serum IgG / IgG1 / IgG2a antibodies and significantly induce the production of cytotoxic T cells, that is, simultaneously enhance humoral and cellular immune responses, and can be used as a vaccine adjuvant in vaccines.
[0066] The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technician familiar with this profession can make some changes or modify the technical contents disclosed above into equivalent embodiments of equivalent changes without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the technical solution of the present invention.
Claims
1. An immune complex based on aescin salt compound, characterized in that: The complex comprises an antigen and an aescin salt compound, and the structure of the aescin salt compound is shown in formula (I): R in formula (I) is a metal salt, including sodium and potassium; the antigen and the aescin salt compound are co-loaded in a carrier, or the antigen and the aescin salt compound are encapsulated in different carriers and then mixed for administration; the carrier is one or more of a microemulsion, aluminum salt particles, and liposomes; the microemulsion carrier contains squalene, Tween 80, and egg yolk lecithin; the liposome contains DOPC, cholesterol, and DSPE-PEG; and the aluminum salt particles contain chondroitin sulfate, aluminum sulfate, and / or aluminum hydroxide.
2. The immune complex according to claim 1, characterized in that The weight ratio of the antigen to the aescin salt compound is 1:0.01-100.
3. The immune complex according to any one of claims 1 to 2, characterized in that It also contains additional adjuvants, which include: aluminum adjuvant; peptidoglycan, lipoteichoic acid, MPLA, imiquimod, resiquimod, bacterial flagellin, Poly I:C; 3pRNA, short double-stranded RNA; muramyl dipeptide MDP, N-acetylglucosamine; β-glucan, trehalose diborate; STING agonist; cholera toxin CT, Escherichia coli heat-labile enterotoxin LT, cholera toxin B subunit; QS21, tomatin, Quil-A; GM-CSF, IL-2, IL-12, IL-6, IFN-γ, lymphocyte chemotactic factor; heat shock protein, A151, GTP-GDP, one or more complexes of dimethyl dioctadecyl quaternary ammonium bromide DDA.
4. The immune complex according to claim 3, characterized in that The additional adjuvant is selected from one or more of the following: aluminum adjuvant, MPLA.
5. Use of the immune complex according to any one of claims 1 to 4 in the preparation of vaccines.
6. A vaccine, characterized in that Contains the immune complex described in any one of claims 1-4.
Citation Information
Patent Citations
Composite immunologic adjuvant and application thereof
CN112294955A
Immunostimulatory composition and use thereof
CN112972670A
Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
CN1739800A
Aescin medicine composition and its prepn process and use
CN1931176A
Mucoadhesive polymer adjuvant-based influenza vaccine
KR1020170010717A
